Answers are grounded in this paper and cite their sources.
Cardiovascular trials often use a composite end point and a time-to-first event model. We sought to compare edoxaban versus warfarin using the win ratio, which offers data complementary to time-to-first event analysis, emphasizing the most severe clinical events.
No takes yet. Share an insight, caveat, or question.
Bergmark et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: